Figure 1. Circulating tumor DNA (ctDNA) kinetics in a patient with POLE-mutant colorectal cancer undergoing therapy using the tumor-informed approach. The patient received FOLFOXIRI and bevacizumab as neoadjuvant chemotherapy and a continued regimen of FOLFOXIRI only as adjuvant chemotherapy.